Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age14-70
SponsorSun Yat-sen University
About this trial
The main purpose of this trial is to investigate and evaluate the efficacy of cryoablation combined with camrelizumab treatment to patients with advanced or inoperable soft tissue sarcomas after standard treatment failure.
Eligibility criteria
Qualifiers
Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
Age≥14 years old, and≤70 years old ;
Pathologically diagnosed as soft tissue sarcomas, and staging for advanced or unresectable patients ;
Patients with standard treatment (such as chemotherapy) failure ;
Disqualifiers
Concurrently having other malignant tumors within 5 years.;
Patients who received major surgeries, conventional chemotherapy, large-area radiotherapy, biotherapy or interventional ablation therapy for anti-tumor treatment within 4 weeks before entering the trial;
known for any component of this test treatment will produce allergic reactions ;
No recovery from previous surgery or treatment-related adverse reactions to < Level 2 CTCAE;
Trial design
Treatments tested in this trial
- Cryoablation therapy + anti-PD-1 antibody
Treatment groups
57 Participants
are divided into 1 treatment groupLocations
1Sun Yat-Sen Univerisity510000, GuangzhouGuangdong, China
Sponsors and collaborators
Sun Yat-sen University
Lead sponsor
Source ClinicalTrials.gov